The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Salvatori, B ^a   Iosue, I ^b   Mangiavacchi, A ^a   Loddo, G ^a   Padula, F ^b   Chiaretti, S ^b   Peragine, N ^b   Bozzoni, I ^a,c   Fazi, F ^b   Fatica, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

Author keywords

Acute myeloid leukemia; E2F7; microRNAs; miR 26a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA 26A; TRANSCRIPTION FACTOR E2F7;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; UPREGULATION;

CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F7 TRANSCRIPTION FACTOR; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MONOCYTES; U937 CELLS;

EID: 84870508415     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.151     Document Type: Article

References (41)

1. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003; 3: 89-101.
2. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011; 2: 95-107.
3. Manfredini R, Trevisan F, Grande A, Tagliafico E, Montanari M, Lemoli R et al. Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Res 1999; 59: 3803-3811.
4. Wang Q, Harrison JS, Uskokovic M, Kutner A, Studzinski GP. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005; 19: 1812-1817.
5. Tagliafico E, Tenedini E, Manfredini R, Grande A, Ferrari F, Roncaglia E et al. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Leukemia 2006; 20: 1751-1758.
6. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-153.
7. Asada M, Yamada T, Fukumuro K, Mizutani S. p21Cip1/WAF1 is important for differentiation and survival of U937 cells. Leukemia 1998; 12: 1944-1950.
8. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18: 1223-1234.
9. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2012; 26: 1-12.
10. Gocek E, Wang X, Liu X, Liu CG, Studzinski GP. MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res 2011; 71: 6230-6239.
11. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736-741.
12. Delgado MD, León J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010; 1: 605-616.
13. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6: 635-645.
14. Bui TV, Mendell JT. Myc: maestro of microRNAs. Genes Cancer 2010; 1: 568-575.
15. Kitaura H, Shinshi M, Uchikoshi Y, Ono T, Iguchi-Ariga SM, Ariga H. Reciprocal regulation via protein-protein interaction between c-Myc and p21 (cip1/waf1/sdi1) in DNA replication and transcription. J Biol Chem 2000; 275: 10477-10483.
16. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-4212.
17. Salvatori B, Iosue I, Djodji Damas N, Mangiavacchi A, Chiaretti S, Messina M et al. Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2. Genes Cancer 2011; 2: 585-592.
18. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
19. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017.
20. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR et al. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 2012; 40: 4615-4625.
21. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71: 225-233.
22. Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni J et al. Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther 2011; 19: 1521-1528.
23. Westendorp B, Mokry M, Groot Koerkamp MJ, Holstege FC, Cuppen E, de Bruin A. E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic Acids Res 2012; 40: 3511-3523.
24. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19: 1038-1048.
25. Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F et al. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 2007; 9: 775-787.
26. Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A et al. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J 2011; 30: 4450-4464.
27. Lammens T, Li J, Leone G, De Veylder L. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol 2009; 19: 111-118.
28. Deng Q, Wang Q, Zong WY, Zheng DL, Wen YX, Wang KS et al. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res 2010; 70: 782-791.
29. Sozzani R, Maggio C, Giordo R, Umana E, Ascencio-Ibanez JT, Hanley-Bowdoin L et al. The E2FD/DEL2 factor is a component of a regulatory network controlling cell proliferation and development in Arabidopsis. Plant Mol Biol 2010; 72: 381-395.
30. Hazar-Rethinam M, Cameron SR, Dahler AL, Endo-Munoz LB, Smith L, Rickwood D et al. Loss of E2F7 expression is an early event in squamous differentiation and causes derepression of the key differentiation activator Sp1. J Invest Dermatol 2011; 131: 1077-1084.
31. Sirma H, Kumar M, Meena JK, Witt B, Weise JM, Lechel A et al. The promoter of human telomerase reverse transcriptase is activated during liver regeneration and hepatocyte proliferation. Gastroenterology 2011; 141: 326-337.
32. Li L, Sarver AL, Alamgir S, Subramanian S. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 2012; 92: 571-583.
33. Di Stefano L, Jensen MR, Helin K. E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J 2003; 22: 6289-6298.
34. Christensen J, Cloos P, Toftegaard U, Klinkenberg D, Bracken AP, Trinh E et al. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription. Nucleic Acids Res 2005; 33: 5458-5470.
35. Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 2010; 70: 3833-3842.
36. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28: 2167-2174.
37. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011; 32: 2-9.
38. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA. 2010; 107: 2183-2188.
39. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51-56.
40. De Marchis ML, Ballarino M, Salvatori B, Puzzolo MC, Bozzoni I, Fatica A. A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of Acute Promyelocitic Leukemia cells. Leukemia 2009; 23: 856-862.
41. Rosa A, Brivanlou AH. A regulatory circuitry comprised of miR-302 and the transcription factors OCT4 and NR2F2 regulates human embryonic stem cell differentiation. EMBO J 2011; 30: 237-248.